1997
|
Sign up to set email alerts
Biodegradable scleral implant for intravitreal controlled release of fluconazole
Search citation statements
Order By: Relevance
Paper Sections
Select...
45
4
1
0
Citation Types
1
28
1
0
Year Published
Range
1998
19982024
2024Publication Types
Select...
39
6
2
Relationship
2
45
Authors
Journals
Cited by 47 publications
(30 citation statements)
References 23 publications
1
28
1
0
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…We did not observe any severe inflammation in the retina, vitreous, sclera, and conjunctiva. Neither did we find inflammatory retinal changes in our previous studies with another sustained drug-delivery system of a PLGA rod to treat PVR [10,11,17,20,24,38]. These findings suggest that the biocompatibility of the device may be clinically acceptable.…”
Section: Discussion
contrasting
confidence: 68%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…We did not observe any severe inflammation in the retina, vitreous, sclera, and conjunctiva. Neither did we find inflammatory retinal changes in our previous studies with another sustained drug-delivery system of a PLGA rod to treat PVR [10,11,17,20,24,38]. These findings suggest that the biocompatibility of the device may be clinically acceptable.…”
Section: Discussion
contrasting
confidence: 68%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…24 Histopathologic results confirmed the good biocompatibility of POE 70 LA 30 . A transient, acute inflammatory reaction was observed in the subconjunctival space, with granulated neutrophils around POE 70 LA 30 by day 4, as previously described for the third-generation POE. 24 This inflammatory reaction resolved within 2 weeks, with neither recurrence nor encapsulation of the biomaterial.…”
Section: Subconjunctival Injections
supporting
confidence: 68%
“…9(B)]. These results show that no retinal damage resulted from the suprachoroidal presence of 100 L of POE 70 LA 30 or its degradation products.…”
Section: Suprachoroidal Injections
mentioning
confidence: 62%
“…Histologic analysis of eyes enucleated 7 days after injection confirmed the good biocompatibility of POE 70 LA 30 . Some inflammatory cells were detected in the corneal stroma and in the anterior chamber.…”
Section: Intracameral Injections
mentioning
confidence: 62%
“…19 Table II 30 were well tolerated, triggering an acute inflammatory reaction that quickly resolved. Polymer persisted in the subconjunctival space without any sign of encapsulation for about 5 weeks, an adequate time period for adjunctive treatment of glaucoma surgery.…”
Section: Discussion
mentioning
confidence: 97%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…We did not observe any severe inflammation in the retina, vitreous, sclera, and conjunctiva. Neither did we find inflammatory retinal changes in our previous studies with another sustained drug-delivery system of a PLGA rod to treat PVR [10,11,17,20,24,38]. These findings suggest that the biocompatibility of the device may be clinically acceptable.…”
Section: Discussion
contrasting
confidence: 68%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…24 Histopathologic results confirmed the good biocompatibility of POE 70 LA 30 . A transient, acute inflammatory reaction was observed in the subconjunctival space, with granulated neutrophils around POE 70 LA 30 by day 4, as previously described for the third-generation POE. 24 This inflammatory reaction resolved within 2 weeks, with neither recurrence nor encapsulation of the biomaterial.…”
Section: Subconjunctival Injections
supporting
confidence: 68%
“…9(B)]. These results show that no retinal damage resulted from the suprachoroidal presence of 100 L of POE 70 LA 30 or its degradation products.…”
Section: Suprachoroidal Injections
mentioning
confidence: 62%
“…Histologic analysis of eyes enucleated 7 days after injection confirmed the good biocompatibility of POE 70 LA 30 . Some inflammatory cells were detected in the corneal stroma and in the anterior chamber.…”
Section: Intracameral Injections
mentioning
confidence: 62%
“…19 Table II 30 were well tolerated, triggering an acute inflammatory reaction that quickly resolved. Polymer persisted in the subconjunctival space without any sign of encapsulation for about 5 weeks, an adequate time period for adjunctive treatment of glaucoma surgery.…”
Section: Discussion
mentioning
confidence: 97%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…We did not observe any severe inflammation in the retina, vitreous, sclera, and conjunctiva. Neither did we find inflammatory retinal changes in our previous studies with another sustained drug-delivery system of a PLGA rod to treat PVR [10,11,17,20,24,38]. These findings suggest that the biocompatibility of the device may be clinically acceptable.…”
Section: Discussion
contrasting
confidence: 68%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…24 Histopathologic results confirmed the good biocompatibility of POE 70 LA 30 . A transient, acute inflammatory reaction was observed in the subconjunctival space, with granulated neutrophils around POE 70 LA 30 by day 4, as previously described for the third-generation POE. 24 This inflammatory reaction resolved within 2 weeks, with neither recurrence nor encapsulation of the biomaterial.…”
Section: Subconjunctival Injections
supporting
confidence: 68%
“…9(B)]. These results show that no retinal damage resulted from the suprachoroidal presence of 100 L of POE 70 LA 30 or its degradation products.…”
Section: Suprachoroidal Injections
mentioning
confidence: 62%
“…Histologic analysis of eyes enucleated 7 days after injection confirmed the good biocompatibility of POE 70 LA 30 . Some inflammatory cells were detected in the corneal stroma and in the anterior chamber.…”
Section: Intracameral Injections
mentioning
confidence: 62%
“…19 Table II 30 were well tolerated, triggering an acute inflammatory reaction that quickly resolved. Polymer persisted in the subconjunctival space without any sign of encapsulation for about 5 weeks, an adequate time period for adjunctive treatment of glaucoma surgery.…”
Section: Discussion
mentioning
confidence: 97%
Abstract